C-MET (MET) Amplification
The C-MET (MET - Mesenchymal-Epithelial Transition factor) encodes a transmembrane tyrosine kinase1, which is an oncoprotein.
The MET gene regulates both cell motility and cell growth2, so normal C-MET expression allows stem cells and progenitor cells to grow invasively. This invasive growth is required to generate new tissues in an embryo, or in an adult in regenerating tissue, such as the liver, or during wound repair3.
MET has been shown to be overexpressed in many tumours including ovarian4, breast5, lung6, thyroid7, stomach8, pancreatic9,10 and colon11,12. This overexpression correlates with a poor prognosis4,13,14. In breast cancers, MET was only shown to be co-expressed with HER2 (ERBB2) in 50% of patients, indicating that it has a significant impact on tumour aggressiveness independently of HER213.
1. Dean M et al., Nature 1985;318:385-8
2. Gherardi E, Stoker M, Cancer Cells 1991;3(6):227-32
3. Boccaccio C, Comoglio PM, Nat Rev Cancer 2006;6(8):637-45
4. Sawada K et al., Cancer Res 2007;67(4):1670-9
5. Carracedo A et al., Breast Cancer Res 2009;11(2):402
6. Zucali PA et al., Ann Oncol 2008;19(9):1605-12
7. Di Renzo MF et al., Oncogene 1992;7:2549-53
8. Kuniyasu H et al., Int J Cancer 1993;55(1):72-5
9. Ebert M et al., Cancer Res 1994;54:5775-8
10. Di Renzo MF et al., Cancer Res 1995;55:1129-38
11. Liu C et al., Oncogene 1992;7(1):181-5
12. Di Renzo MF et al., Clin Cancer Res 1995;1:147-54
13. Miyamoto et al., Br J Cancer. 2011 Jun 28;105(1):131-8
14. Lengyel E et al., Int J Canc 2005;113:678-82
- Area of Interest*
- Breast Cancer, Pancreatic Cancer, Thyroid Cancer, Ovarian Cancer, Lung Cancer, Sarcoma
This product is intended to be used on formalin-fixed paraffin-embedded (FFPE) tissues.
*Disease information supported by the literature and is not a reflection of the intended purpose of this product.